21:53 , May 29, 2019 |  BC Extra  |  Company News

Amicus bolsters rare disease gene therapy pipeline with expanded UPenn deal

Amicus has added three more rare disease gene therapy programs to its pipeline through an expansion of its deal with the University of Pennsylvania, with the option to add at least a dozen more. The...
17:52 , Oct 26, 2018 |  BC Week In Review  |  Company News

Ultragenyx exercises option to Regenxbio gene therapy

Rare disease company Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said it will exercise its option under a 2015 deal to acquire exclusive rights from RegenxBio Inc. (NASDAQ:RGNX) to develop and commercialize a gene therapy to treat cyclin...
17:57 , Jul 20, 2018 |  BC Week In Review  |  Company News

Takeda, Ovid expand TAK-935 collaboration with three new trials

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Ovid Therapeutics Inc. (NASDAQ:OVID) expanded their collaboration for TAK-935 (OV935) to include three new trials in pediatric populations, including in two additional rare epilepsy syndromes. The partners expect to...
23:26 , Dec 7, 2017 |  BC Extra  |  Clinical News

Sage jumps on Phase II data for MDD candidate

Sage Therapeutics Inc. (NASDAQ:SAGE) gained $64.37 (70%) to $156.27 on Thursday after reporting that SAGE-217 met the primary endpoint in a Phase II trial to treat moderate to severe major depressive disorder. Sage added over...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
20:20 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $258.8 million through the sale...
22:12 , Sep 15, 2017 |  BC Extra  |  Financial News

Follow-on roundup: Array, Marinus, T2

Cancer company Array BioPharma Inc. (NASDAQ:ARRY), neurology company Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), and diagnostics play T2 Biosystems Inc. (NASDAQ:TTOO) each priced follow-on offerings, raising more than $270 million. Array raised $225 million late Thursday through...
21:08 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Ganaxolone: Preliminary Ph II data

Preliminary data from 4 patients with cyclin dependent kinase like 5 (CDKL5) epilepsy in an open-label, U.S. and Italian Phase II trial showed that once-daily doses of up to 1,800 mg/kg oral ganaxolone for an...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Ganaxolone: Additional Phase II data

Additional data from 11 female patients ages 4-15 with protocadherin 19 (PCDH19) epilepsy and uncontrolled seizures despite antiepileptic pharmacotherapy in an open-label, U.S. and Italian Phase II trial showed that adjunct treatment with up to...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Company News

MiaMed, Amicus Therapeutics deal

Amicus acquired neurology company MiaMed and its preclinical program for cyclin-dependent kinase-like 5 deficiency. MiaMed received $6.5 million up front in cash and stock and is eligible for up to $18 million in clinical and...